Cachexia Research Laboratory, Exercise Science Research Center, Department of Health, Human Performance and Recreation, University of Arkansas, Fayetteville, Arkansas, United States.
Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee, United States.
J Appl Physiol (1985). 2023 Sep 1;135(3):655-672. doi: 10.1152/japplphysiol.00196.2023. Epub 2023 Aug 3.
Cancer cachexia is clinically defined by involuntary weight loss >5% in <6 mo, primarily affecting skeletal muscle. Here, we aimed to identify sex differences in the onset of colorectal cancer cachexia with specific consideration to skeletal muscle contractile and metabolic functions. Eight-weeks old BALB/c mice (69 males, 59 females) received subcutaneous C26 allografts or PBS vehicle. Tumors were developed for 10-, 15-, 20-, or 25 days. Muscles and organs were collected, in vivo muscle contractility, protein synthesis rate, mitochondrial function, and protein turnover markers were assessed. One-way ANOVA within sex and trend analysis between sexes were performed, < 0.05. Gastrocnemius and tibialis anterior (TA) muscles became atrophic in male mice at 25 days, whereas female mice exhibited no significant differences in muscle weights at endpoints despite presenting hallmarks of cancer cachexia (fat loss, hepatosplenomegaly). We observed lowered muscle contractility and protein synthesis concomitantly to muscle mass decay in males, with higher proteolytic markers in muscles of both sexes. mRNA of was lower in TA, whereas was higher in gastrocnemius after 25 days in male mice, with no significant effect in female mice. Our data suggest relative protections to skeletal muscle in females compared with males despite other canonical signs of cancer cachexia and increased protein degradation markers; suggesting we should place onus upon nonmuscle tissues during early stages of cancer cachexia in females. We noted potential protective mechanisms relating to skeletal muscle contractile and mitochondrial functions. Our findings underline possible heterogeneity in onset of cancer cachexia between biological sexes, suggesting the need for sex-specific approaches to treat cancer cachexia. Our study demonstrates biological-sex differences in phenotypic characteristics of cancer cachexia between male and female mice, whereby females display many common characteristics of cachexia (gonadal fat loss and hepatosplenomegaly), protein synthesis markers alterations, and common catabolic markers in skeletal muscle despite relatively preserved muscle mass in early-stage cachexia compared with males. Mechanisms of cancer cachexia appear to differ between sexes. Data suggest need to place onus of early cancer cachexia detection and treatment on nonmuscle tissues in females.
癌症恶病质的临床定义为 6 个月内非自愿性体重下降>5%,主要影响骨骼肌。在这里,我们旨在确定结直肠癌恶病质发病的性别差异,并特别考虑骨骼肌收缩和代谢功能。8 周龄 BALB/c 小鼠(雄性 69 只,雌性 59 只)接受皮下 C26 同种异体移植物或 PBS 载体。肿瘤发展 10、15、20 或 25 天。收集肌肉和器官,评估体内肌肉收缩力、蛋白质合成率、线粒体功能和蛋白质周转率标志物。对性别内的单向方差分析和性别间的趋势分析进行了分析, < 0.05。25 天时,雄性小鼠的腓肠肌和比目鱼肌发生萎缩,而雌性小鼠尽管表现出癌症恶病质的特征(脂肪丢失、肝脾肿大),但终点时肌肉重量没有显著差异。我们观察到雄性肌肉质量下降时同时伴有肌肉收缩力和蛋白质合成下降,两种性别肌肉的蛋白水解标志物均升高。25 天后雄性小鼠比目鱼肌的 mRNA 降低,而腓肠肌的 mRNA 升高,雌性小鼠无显著影响。与其他典型的癌症恶病质和增加的蛋白质降解标志物相比,我们的数据表明女性的骨骼肌相对受到保护;这表明我们应该在女性癌症恶病质的早期阶段将重点放在非肌肉组织上。我们注意到与骨骼肌收缩和线粒体功能相关的潜在保护机制。我们的研究结果强调了生物性别之间癌症恶病质发病的可能异质性,表明需要针对癌症恶病质采取性别特异性方法。我们的研究表明,雄性和雌性小鼠之间癌症恶病质的表型特征存在生物学性别差异,即雌性表现出恶病质的许多常见特征(性腺脂肪丢失和肝脾肿大)、蛋白质合成标志物改变以及骨骼肌中常见的分解代谢标志物,尽管与雄性相比,在早期恶病质中肌肉质量相对保存。癌症恶病质的机制似乎在性别之间有所不同。数据表明,需要将早期癌症恶病质的检测和治疗的责任放在女性的非肌肉组织上。